Scribe Therapeutics Inc. (SCTX) - What Are Brokerages Saying About This Stock?

Scribe Therapeutics logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is “Moderate Buy”: Four of six analysts rate Scribe Therapeutics a buy, while one rates it hold and one sell; the average 12-month price target is $51.75.
  • The article reports SCTX opened at $15.37 and says the company missed quarterly earnings expectations, posting a loss of $0.68 per share versus estimates of $0.42 per share.
  • Important caveat: Although the article discusses SCTX as a Nasdaq-listed stock and reports a Goldman Sachs stake, it also says Scribe Therapeutics is privately held and that a Nasdaq listing under SCTX could not be verified.
  • MarketBeat previews top five stocks to own in December.

Scribe Therapeutics Inc. (NASDAQ:SCTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $51.75.

Several equities research analysts recently weighed in on the stock. Weiss Ratings began coverage on shares of Scribe Therapeutics in a report on Tuesday, October 20th. They issued a "sell (e-)" rating for the company. Wall Street Zen raised shares of Scribe Therapeutics to a "hold" rating in a research note on Saturday, August 1st. Guggenheim initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set a "buy" rating and a $50.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an "overweight" rating and a $60.00 price target for the company. Finally, HC Wainwright started coverage on shares of Scribe Therapeutics in a research note on Monday, August 31st. They issued a "buy" rating and a $60.00 price target for the company.

Get Our Latest Stock Analysis on SCTX

Institutional Investors Weigh In On Scribe Therapeutics

A hedge fund recently bought a new stake in Scribe Therapeutics stock. Goldman Sachs Group Inc. purchased a new stake in shares of Scribe Therapeutics Inc. (NASDAQ:SCTX - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 21,635 shares of the company's stock, valued at approximately $398,000. Goldman Sachs Group Inc. owned approximately 0.11% of Scribe Therapeutics as of its most recent filing with the SEC.

Scribe Therapeutics Price Performance

Shares of SCTX opened at $15.37 on Tuesday. The company has a market capitalization of $290.95 million and a PE ratio of -1.41. The stock's fifty day moving average price is $20.86. Scribe Therapeutics has a 12-month low of $13.50 and a 12-month high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.64 million during the quarter. Sell-side analysts predict that Scribe Therapeutics will post -3.68 EPS for the current year.

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

See Also

Analyst Recommendations for Scribe Therapeutics (NASDAQ:SCTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Scribe Therapeutics Right Now?

Before you consider Scribe Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scribe Therapeutics wasn't on the list.

While Scribe Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines